期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Allogeneic peripheral blood stem cell transplantation in the treatment of severe aplastic anemia and severe infection 被引量:2
1
作者 万理萍 颜式可 +5 位作者 王椿 杨新潮 周柱 高彦荣 蔡琦 张冰 《Chinese Medical Journal》 SCIE CAS CSCD 2003年第5期676-678,共3页
Objective To investigate the efficacy of allogeneic peripheral blood stem cell transplantation (PBSCT) in the treatment of severe aplastic anemia (SAA) and severe infection. Methods A patient with SAA and pseudomon... Objective To investigate the efficacy of allogeneic peripheral blood stem cell transplantation (PBSCT) in the treatment of severe aplastic anemia (SAA) and severe infection. Methods A patient with SAA and pseudomonas aeruginosa septicemia was treated with PBSCT from an HLA-identical sibling with cyclophosphamide (CY) and total body irradiation (TBI) for conditioning. The patient was infused with 20.3×108/kg mononuclear cells including 61.0×106/kg CD34+cells following the conditioning regimen. Results Twelve days after PBSCT, the absolute neutrophil count (ANC) of 1.0×109/L was achieved, with platelet count >50×109/L at twenty days. The donor origin of engraftment was confirmed by polymerase chain reaction (PCR) analysis of short tandem repeats at the end of the first, sixth and twelfth month. The patient’s body temperature dropped to normal level when her ANC reached 0.5×109/L on day 10, and the bacterial culture of blood sample became negative subsequently. Symptoms and signs of acute or chronic graft versus host disease (GVHD) were not observed in 30 months after PBSCT. Conclusions Hematopoiesis was reconstituted shortly after PBSCT. The combination of CY and TBI and the infusion of sufficient peripheral blood stem cells may contribute to the successful engraftment. PBSCT may be considered as the first choice when hematopoietic stem cell transplantation is needed for SAA patients complicated with severe infection. 展开更多
关键词 aplastic anemia · septicemia · transplantation · homologous hemopoietic stem cell transplantation
原文传递
Impact of COVID-19 in patients with lymphoid malignancies
2
作者 John Charles Riches 《World Journal of Virology》 2021年第3期97-110,共14页
The first cases of coronavirus disease 2019(COVID-19)were detected in Wuhan,China,in December 2019.Since this time a concerted global effort of research and observational data gathering has meant that a great deal has... The first cases of coronavirus disease 2019(COVID-19)were detected in Wuhan,China,in December 2019.Since this time a concerted global effort of research and observational data gathering has meant that a great deal has been learnt about the impact of COVID-19 in patients with lymphoid malignancies.Approximately onethird of patients with lymphoid malignancies who acquire COVID-19 and have it severely enough to require hospital assessment will die from this infection.Major risk factors for a poor outcome are age and co-morbidities,but when these are taken into account lymphoma patients have a slightly greater than 2-fold increased risk compared to the general population.Notably,despite early concerns regarding the particular vulnerability of lymphoma patients due to the immunosuppressive effects of therapy,active treatment,including B-cell depleting agents such as rituximab,do not appear to be associated with an increased risk of a poorer outcome.Indeed,some treatments such as ibrutinib may be beneficial due to their modulation of the potential fatal hyperinflammatory phase of infection.There are risks associated with hemopoietic stem cell transplantation,but the collective experience is that these can be minimized by preventive strategies and that the majority of transplant recipients with COVID-19 infection will survive.Many questions remain including those regarding the outcome of COVID-19 infection in the rarer lymphoid malignancies and the efficacy of COVID-19 vaccines in lymphoma patients.This review aims to discuss these issues and present a summary of the current knowledge of the impact of COVID-19 in lymphoid malignancies. 展开更多
关键词 COVID-19 LYMPHOMA LEUKEMIA CHEMOIMMUNOTHERAPY hemopoietic stem cell transplantation VACCINATION
下载PDF
Comparative Study of Tiaoxue Yisui Recipe with SSL Regimen in Treating Infantile Chronic Aplastic Anemia
3
作者 阎丰书 李贵宾 +3 位作者 李凤学 朱爱英 于敏志 张爱华 《Chinese Journal of Integrative Medicine》 SCIE CAS 1998年第4期255-258,共4页
Objective: To find the effective method in treating infantile chronic aplastic anemia (ICAA) by using traditional Chinese medicine (TCM). Methods: Seventy-eight cases of ICAA were observed, 48 in the treated group wer... Objective: To find the effective method in treating infantile chronic aplastic anemia (ICAA) by using traditional Chinese medicine (TCM). Methods: Seventy-eight cases of ICAA were observed, 48 in the treated group were treated with Tiaoxue Yisui recipe, and 30 cases in the control group with SSL regimen. Results: The remission rate and total effective rate in the treated group were 52. 08% and 81. 25% respectively,which were higher than those in the control group (P < 0. 05). After one year's treatment the ratio of hemopoietic and non-hemopoietic cells in the treated group was higher than that in the control group (P< 0. 05). Conclusion: Tiaoxue Yisui recipe could improve the living quality of ICAA patients. The therapeutical mechanism of the recipe might be related to its promoting the proliferation of hemopoietic stem cells and regulating the immune function. 展开更多
关键词 infantile chronic aplastic anemia Tiaoxue Yisui recipe hemopoietic stem cell IMMUNOREGULATION
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部